These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 23897281)

  • 1. In vitro characterization of a liposomal formulation of celecoxib containing 1,2-distearoyl-sn-glycero-3-phosphocholine, cholesterol, and polyethylene glycol and its functional effects against colorectal cancer cell lines.
    Erdoğ A; Putra Limasale YD; Keskin D; Tezcaner A; Banerjee S
    J Pharm Sci; 2013 Oct; 102(10):3666-77. PubMed ID: 23897281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Celecoxib-loaded liposomes: effect of cholesterol on encapsulation and in vitro release characteristics.
    Deniz A; Sade A; Severcan F; Keskin D; Tezcaner A; Banerjee S
    Biosci Rep; 2010 Jun; 30(5):365-73. PubMed ID: 19900165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In-vitro characterisation of a novel celecoxib microbead formulation for the treatment and prevention of colorectal cancer.
    McDonald BF; Quinn AM; Devers T; Cullen A; Coulter IS; Marison IW; Loughran ST
    J Pharm Pharmacol; 2015 May; 67(5):685-95. PubMed ID: 25650335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simple passive equilibration method for loading carboplatin into pre-formed liposomes incubated with ethanol as a temperature dependent permeability enhancer.
    Wehbe M; Malhotra A; Anantha M; Roosendaal J; Leung AWY; Plackett D; Edwards K; Gilabert-Oriol R; Bally MB
    J Control Release; 2017 Apr; 252():50-61. PubMed ID: 28286316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stable and sustained release liposomal formulations of celecoxib: In vitro and in vivo anti-tumor evaluation.
    Matbou Riahi M; Sahebkar A; Sadri K; Nikoofal-Sahlabadi S; Jaafari MR
    Int J Pharm; 2018 Apr; 540(1-2):89-97. PubMed ID: 29371019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidermal growth factor receptor-targeted immunoliposomes for delivery of celecoxib to cancer cells.
    Limasale YD; Tezcaner A; Özen C; Keskin D; Banerjee S
    Int J Pharm; 2015 Feb; 479(2):364-73. PubMed ID: 25595386
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil.
    Al Asmari AK; Ullah Z; Tariq M; Fatani A
    Drug Des Devel Ther; 2016; 10():205-15. PubMed ID: 26834457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study on the role of cholesterol and phosphatidylcholine in various features of liposomal doxorubicin: From liposomal preparation to therapy.
    Farzaneh H; Ebrahimi Nik M; Mashreghi M; Saberi Z; Jaafari MR; Teymouri M
    Int J Pharm; 2018 Nov; 551(1-2):300-308. PubMed ID: 30243944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intra-articular delivery of liposomal celecoxib-hyaluronate combination for the treatment of osteoarthritis in rabbit model.
    Dong J; Jiang D; Wang Z; Wu G; Miao L; Huang L
    Int J Pharm; 2013 Jan; 441(1-2):285-90. PubMed ID: 23194887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PEGylated Liposomes of Meloxicam: Optimization by Quality by Design, in vitro Characterization and Cytotoxicity Evaluation.
    Shaji J; Menon I
    Pharm Nanotechnol; 2017; 5(2):119-137. PubMed ID: 28462699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression.
    Sade A; Tunçay S; Cimen I; Severcan F; Banerjee S
    Biosci Rep; 2012 Feb; 32(1):35-44. PubMed ID: 21401528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multivesicular liposomes bearing celecoxib-beta-cyclodextrin complex for transdermal delivery.
    Jain SK; Gupta Y; Jain A; Bhola M
    Drug Deliv; 2007 Aug; 14(6):327-35. PubMed ID: 17701522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liposomes as Delivery System of a Sn(IV) Complex for Cancer Therapy.
    Corvo ML; Mendo AS; Figueiredo S; Gaspar R; Larguinho M; Guedes da Silva MF; Baptista PV; Fernandes AR
    Pharm Res; 2016 Jun; 33(6):1351-8. PubMed ID: 27033349
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-polymer hybrid nanoparticles as a new generation therapeutic delivery platform: a review.
    Hadinoto K; Sundaresan A; Cheow WS
    Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt A):427-43. PubMed ID: 23872180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development and optimization of an injectable formulation of copper diethyldithiocarbamate, an active anticancer agent.
    Wehbe M; Anantha M; Shi M; Leung AW; Dragowska WH; Sanche L; Bally MB
    Int J Nanomedicine; 2017; 12():4129-4146. PubMed ID: 28615941
    [TBL] [Abstract][Full Text] [Related]  

  • 16. pH-Sensitive PEGylated liposomes for delivery of an acidic dinitrobenzamide mustard prodrug: Pathways of internalization, cellular trafficking and cytotoxicity to cancer cells.
    Yang MM; Wilson WR; Wu Z
    Int J Pharm; 2017 Jan; 516(1-2):323-333. PubMed ID: 27871834
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted liposome delivery system for combretastatin A4: formulation optimization through drug loading and in vitro release studies.
    Nallamothu R; Wood GC; Kiani MF; Moore BM; Horton FP; Thoma LA
    PDA J Pharm Sci Technol; 2006; 60(3):144-55. PubMed ID: 17089683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liposomal gels for site-specific, sustained delivery of celecoxib: in vitro and in vivo evaluation.
    Fetih G; Fathalla D; El-Badry M
    Drug Dev Res; 2014 Jun; 75(4):257-66. PubMed ID: 24939834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentration-dependent differing actions of the nonsteroidal anti-inflammatory drug, celecoxib, in distearoyl phosphatidylcholine multilamellar vesicles.
    Sade A; Banerjee S; Severcan F
    J Liposome Res; 2010 Jun; 20(2):168-77. PubMed ID: 19848445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cell-penetrating Peptide-coated Liposomes for Drug Delivery Across the Blood-Brain Barrier.
    Yuan BO; Zhao Y; Dong S; Sun Y; Hao F; Xie J; Teng L; Lee RJ; Fu Y; Bi YE
    Anticancer Res; 2019 Jan; 39(1):237-243. PubMed ID: 30591464
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.